Table 3.
Clinical and Treatment Characteristics for Patients at Time of Metastatic and/or Recurrent Disease
| Variable | Total (n = 164) |
Short-Term Treatment Duration (n = 54) |
Intermediate Treatment Duration (n = 55) |
Long-Term Treatment Duration (n = 55) |
P |
|---|---|---|---|---|---|
| DFI, years | .729 | ||||
| 1.3 (0- 14.3) |
1.3 (0-14.3) | 1.3 (0-12.7) | 1.2 (0-13.4) | ||
|
Sites at Initial Metastatic Diagnosis
and/or Recurrence |
.608 | ||||
| 2 (1-5) | 3 (1-5) | 2 (1-4) | 2 (1-5) | ||
|
Sites of Disease at Initial Metastatic
Diagnosis and/or Recurrence a |
|||||
| Soft tissueb | 85 (51.8) | 32 (59.3) | 25 (45.5) | 28 (50.9) | .368 |
| Bone | 86 (52.4) | 28 (51.8) | 29 (52.7) | 29 (52.7) | 1.0 |
| Liver | 82 (50.0) | 26 (48.2) | 27 (49.1) | 29 (52.7) | .923 |
| Lung | 59 (36.0) | 25 (46.3) | 17 (30.9) | 17 (30.9) | .164 |
| CNS | 12 (7.3) | 3 (5.6) | 7 (12.7) | 2 (3.6) | .212 |
| Other | 23 (14.0) | 9 (16.7) | 6 (10.9) | 8 (14.6) | .666 |
|
Duration of First Metastatic Anti-
HER2 Therapy, mo |
<.0001 | ||||
| 10.3 (1.5- 110.8) |
3.9 (1.5-7.1) | 10.3 (7.2-14.0) | 22.9 (14.1-105.7) | ||
|
Type of First Trastuzumab-Based
Regimen |
.116 | ||||
| Monotherapy | 13 (7.9) | 6 (11.1) | 2 (3.6) | 5 (9.1) | |
| Concomitant with endocrine therapy |
9 (5.5) | 0 (0) | 7 (12.7) | 2 (3.6) | |
| Concomitant with chemotherapy | 135 (82.3) |
46 (83.6) | 42 (76.4) | 47 (85.5) | |
| With taxane based regimen | 34 (25.2) | 11 (23.9) | 8 (19.1) | 15 (31.9) | |
| With vinorelbine | 87 (64.4) | 29 (63.0) | 29 (69.0) | 29 (61.7) | |
| With other agent | 14 (10.4) | 6 (13.1) | 5 (11.9) | 3 (6.4) | |
| Concomitant with other anti-HER2 target agent |
7 (4.3) | 2 (3.7) | 4 (7.3) | 1 (1.8) | |
|
Best Clinical Response During First-
Line Therapy |
.352 | ||||
| Complete response | 4 (2.4) | 0 (0) | 3 (5.5) | 1 (1.8) | |
|
CNS Progression During First-Line
Therapy (Non-CNS Disease Controlled) |
<.0001 | ||||
| 39 (23.8) | 3 (5.6) | 10 (18.2) | 26 (47.2) | ||
|
Switch to Trastuzumab Monotherapy
or Trastuzumab and Endocrine During First-Line Therapy |
<.0001 | ||||
| 59 (36.0) | 3 (5.5) | 19 (34.6) | 37 (67.3) |
Data are presented as median (range) or n (%).
Abbreviations: CNS = central nervous system; DFI = disease-free interval.
a
Proportion of patients does not add up to 100% because patients could have more than 1 site of recurrence.
b
Soft tissue includes: chest wall, breast, local and/or distant lymph nodes, or skin.